null - FindTrial

N/A - ARNCOMBI

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2021-002174-52-FR

Enrollment

400

Registered

2021-05-06

Start date

2021-05-19

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Trade Name: COMIRNATY Product Name: COMIRNATY Pharmaceutical Form: Dispersion for injection Other descriptive name: COVID-19 mRNA vaccine (nucleoside-modified) Concentration unit: µg/ml microgram(s)/m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

France

Contacts

Public ContactFatiha ACED-DJENNAOUI

Assistance Publique -Hopitaux de Paris

fatiha.djennaoui@aphp.fr330144841708

Outcome results